SCHEMBL3667418

SCHEMBL3667418

CCOC(=O)C1CCCN(c2nc(Cl)ncc2N)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 5/20 0.53
MAPK1 P28482 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
HSD17B10 Q99714 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
HPGD P15428 2/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 5/20 0.51
LMNA P02545 1/20 0.51
SHMT2 P34897 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPSR1 Q6W5P4 5/20 0.49
TSHR P16473 2/20 0.48
CASP1 P29466 1/20 0.48
MMP13 P45452 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12184895 0.89 ALDH1A1 (0.55) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL4082886 0.84 ALDH1A1 (0.57) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL4076212 0.83 KDM4E (0.48) ALDH1A1KDM4EHSD17B10HPGDKMT2A
SCHEMBL2635948 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL29438234 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL12185358 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL1018947 0.78 NPSR1 (0.50) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL20284533 0.76 ALDH1A1 (0.51) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL22149667 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1NPC1RAB9A
SCHEMBL29891157 0.76 ALDH1A1 (0.54) ALDH1A1KDM4EMAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139892-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-01-06 EP disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
WO-2008113711-A1 SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-25 WO disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 ALDH1A1 1365/4885KDM4E 1150/4885MAPK1 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.